Harbin Pharmaceutical Group Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Harbin Pharmaceutical Group Company Limited with three other
companies in this sector in China:
Shanghai Fosun Pharmaceutical (Group) Company Limited
sales of 14.51 billion Chinese Renmimbi [US$2.20 billion]
of which 70%
was Pharmaceutical Manufacturing and R&D),
Shenzhen Neptunus Bioengineer
(13.61 billion Chinese Renmimbi [US$2.06 billion]
of which 84%
was Pharmaceutical Distribution), and
Tasly Pharmaceutical Group Company Limited
(13.95 billion Chinese Renmimbi [US$2.12 billion]
of which 51%
was Medicine Commerce).
Harbin Pharmaceutical Group Company Limited reported sales of 14.13 billion Chinese Renmimbi (US$2.14 billion)
December of 2016.
decrease of 10.9%
versus 2015, when the company's sales were 15.85 billion Chinese Renmimbi.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Harbin Pharmaceutical Group Company Limited had sales
of 13.47 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 42.4% decline
in Other Operating, from 74.48 million Chinese Renmimbi to 42.87 million Chinese Renmimbi.
There were also decreases in sales in
Medicine Trade (down 7.1% to 8.98 billion Chinese Renmimbi)
Medicine Industry (down 15.5% to 5.10 billion Chinese Renmimbi)